Lupus

The approval was based on findings from the Belimumab International Study in Lupus Nephritis (BLISS-LN) study.

In today's interview, our focus is on patient perspectives. During the American College of Rheumatology annual meeting last month, Juana Mata shared her story of a life living with lupus. Getting an accurate diagnosis wasn't easy, but eventually she found a doctor and treatment that's working for her. In today's interview, Kim Gorgens, a psychologist and Rheumatology Network board member interviews Juana and her sister, Estela, who describe turning a lupus diagnosis into a positive force for change through advocacy. The sisters have created a non-profit group called Looms for Lupus in which they embrace art therapy to relieve stress.

In this episode of Overdrive, the Rheumatology Network podcast, Dr. Kim Gorgens interviews two sisters who've turned a negative healthcare experience into a positive force for change in the lupus community through advocacy. They shared their story during the Patient Perspectives session at the annual meeting of the American College of Rheumatology which was held last month. In this interview, they share their story with Dr. Gorgens.

Anxiety and depression are not uncommon among lupus patients, show studies recently presented at the annual meeting of the American College of Rheumatology.

Patients with SLE or RA had comparable mean QTc length, regardless of whether or not they received hydroxychloroquine treatment

At this year's annual meeting of the American College of Rheumatology, there were a number of studies presented on different treatments for lupus. It's an exciting time in lupus research says Dr. Richard Furie, chief of rheumatology at Northwell Health in New York. In today's one on one interview, he breaks down some of the lupus studies presented at the meeting

Black patients with lupus have a threefold higher stroke risk and a 24-fold higher ischemic heart disease risk than other ethnic or racial groups with the condition, researchers say.

Patients with systemic lupus erythematous (SLE) who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals on electrocardiogram (EKG), even if they have chronic kidney disease (CKD), according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

Lessons learned from antimalarial drug shortages during the COVID-19 pandemic: rheumatic disease patients in African and South-East Asia had difficulty obtaining antimalarials as compared to counterparts in the Americas and Europe. Shortages led to worse mental and physical health outcomes. Antimalarials did not protect patients from COVID-19.

Welcome to Overdrive, the podcast from Rheumatology Network. This week marks the start of the 2020 annual meeting of the American College of Rheumatology. Some of the studies we're covering include new therapies for lupus nephritis, the impact of COVID-19 on rheumatic disease patients, and pregnancy outcomes in ILD patients. Today, Dr. Fotios Koumpouras of the Yale School of Medicine, highlights some studies you won't want to miss at this year's meeting.

This week marks the start of the 2020 annual meeting of the American College of Rheumatology. Some of the studies we're covering include new therapies for lupus nephritis. Belimumab was shown recently to improve renal outcomes in lupus nephritis patients when added to standard of care. It will likely emerge as a significant treatment option, says Dr. Fotios Koumpouras, fellowship program director for rheumatology at Yale School of Medicine and a Rheumatology Network board member. Dr. Koumpouras breaks down his highlights in this interview.

Barriers to care for lupus patients has been well-document over the years. And, now, a consortium called the Addressing Lupus Pillars for Health Advancement (ALPHA) Project, has come up with a roadmap designed to resolve barriers to care.

The monoclonal antibody has built on its 18-month portfolio with sustained renal benefits for the at-need patient group.

New survey findings show the antimalarial drug's promotion for potential SARS-CoV-2 benefit early into the pandemic led to needing patients losing access.

In this week's news roundup from Rheumatology Network, we highlight more studies presented at Kidney Week, the American Society of Nephrology Kidney Week annual meeting which wrapped this week. Among the stories we covered, includes a possible new treatment for kidney transplant patients with gout, new hope in a new treatment for lupus nephritis and the American College of Rheumatology launches a project to treat underserved lupus patients. These and other headlines are included in this week's news roundup.

The American College of Rheumatology has launched a project designed to resolve inequities in care for patients with systemic lupus erythematosus, a condition that is two or three times more common among ethnic minorities. In this interview, S. Sam Lim, M.D., MPH, chair of ACR’s Collaborative Initiatives Special Committee, tells us more about the project.

Anti-inflammatory and immunosuppressive agents are the two primary classes of drugs used to treat lupus nephritis. Now, a new study shows that the addition of the monoclonal antibody belimumab to standard therapy may make a meaningful difference in this hard-to-treat patient population.

A possible new treatment for advanced lupus nephritis passes a phase two trial, according to a study presented at Kidney Week, the annual meeting of the American Society for Nephrology. The treatment, a CD20 antagonist called obinutuzumab, led to improvements in 41 percent of patients with lupus nephritis—a condition that affects one in 60 people with systemic lupus.

From COVID-19 presentations to emerging new therapies for chronic kidney disease, Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics, offers his take on the most memorable moments from the American Society for Nephrology/Kidney Week annual meeting which wrapped this week.

Treatments for lupus nephritis can cost patients over $50,000 a year, according to a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

Belimumab (Benlysta, GlaxoSmithKline) can improve the kidney health of people with lupus nephritis, a new phase 3 clinical trial suggests.

Today, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.

Type I Interferon Inhibition Could Benefit Systemic Lupus Erythematosus

Cognitive impairment can be an ongoing issue for patients with rheumatic disease, such as lupus. A proper diagnosis includes a battery of tests, says Noa Shwartz, M.D., a physician-researcher with Albert Einstein College of Medicine in New York.